



Promising Sofra™ results from overseas company

Highlights

- BioRay Pharmaceutical named as 2024 Material Transfer Agreement counterparty
- BioRay's results using Sofra drugs confirm targeted anti-inflammatory activity
- Results represent external validation of robustness of Sofra data
- Demonstrates broad potential of Sofra technology platform

Sydney, 11 June 2025: Innovative clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce positive data generated by an overseas company that has tested novel assets from the Sofra™ platform.

In 2024, Noxopharm signed a Material Transfer Agreement (MTA) with [BioRay Pharmaceutical](#), a pioneer in China's biopharmaceutical industry focusing on immune-mediated diseases.

This was just one of several MTAs with international companies, which are now exploring the versatility, performance and commercial potential of Noxopharm's Sofra assets.

BioRay has over 1,800 employees globally, with main sites in Taizhou, Hangzhou, Shanghai, and San Diego, and its extensive autoimmune and oncology portfolio includes eight marketed products and over 10 clinical-stage drug candidates. It operates a fully integrated platform with end-to-end capabilities across drug discovery, clinical development, manufacturing and commercialisation.

BioRay decided to investigate Noxopharm's oligonucleotides as part of its research into autoimmune diseases, specifically looking at how the oligos could be used as targeted drugs in the context of antibody-drug conjugates (ADCs). A conjugated drug is one that has been bound to another molecule, such as a protein or polymer, for targeted delivery into the body.

The data showed two results:

- Conjugation to a specific Noxopharm oligo could be achieved.
- The conjugated drug significantly improved the performance of one of BioRay's own antibodies designed to target autoimmune disease, further reducing inflammation as represented by a key biological marker.




Figure: The study demonstrated that the BioRay antibody in combination with the Sofra oligo (blue line) reduced a key inflammation marker significantly more than the antibody alone (red line).

BioRay will continue its work examining Noxopharm’s assets over the coming months, conducting further studies together with its own drugs.

BioRay Head of R&D Dr Gang Chen said: “We are delighted to announce our strategic collaboration with Noxopharm and are very impressed with the efficacy of the asset supplied to us. The encouraging research findings not only confirm the cutting-edge value of the Sofra platform, but also highlight the tremendous potential of our joint development efforts.”

Noxopharm CEO Dr Gisela Mautner said: “We would like to express our thanks to BioRay for committing time and resources to examine our highly innovative assets, which can support companies in enhancing the performance of their drugs. We are delighted that our Sofra drugs have shown strong anti-inflammatory results in studies by an independent company, therefore validating the robustness of our data.”

“Our MTA with BioRay is just one of several with companies around the world, and we are pleased that we are off to such a good start with these results. Sofra technology is versatile and has numerous use cases, and in the months ahead we aim to continue demonstrating why this technology is so promising.”

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms

For personal use only

– Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only